Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01540409|
Recruitment Status : Unknown
Verified November 2016 by Sarepta Therapeutics.
Recruitment status was: Active, not recruiting
First Posted : February 28, 2012
Last Update Posted : November 25, 2016
|Condition or disease||Intervention/treatment||Phase|
|Duchenne Muscular Dystrophy (DMD)||Drug: AVI-4658 (Eteplirsen)||Phase 2|
This is an open label, multiple dose extension study to assess the ongoing efficacy, safety, and tolerability of weekly intravenous (IV) infusions of eteplirsen in DMD subjects who have successfully completed Study 4658-us 201.
Subjects will have the opportunity to enroll in this study during the last visit of Study 4658-us-201 (Week 28). Eligible subjects will receive once weekly IV infusions of eteplirsen (50 or 30 mg/kg) for an additional 212 weeks. Subjects will receive the same dose of eteplirsen they received in Study 4658-us-201. Subjects will thereafter continue to receive once weekly IV infusions of eteplirsen for up to an additional 72 week period (through week 284). If commercial eteplirsen becomes available during this additional 72 week period, participation in the study will be discontinued as subjects transition to commercial eteplirsen.
Safety, efficacy, pharmacokinetic (PK), and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored.
If review of data from this open label study suggests that continued treatment with eteplirsen is warranted, this study may be extended by protocol amendment or subjects who successfully complete this study may have the opportunity to participate in a separate follow on, open label eteplirsen study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||April 2016|
|Estimated Study Completion Date :||February 2017|
Experimental: AVI-4658 (Eteplirsen)
Multiple-Dose Extension Study
Drug: AVI-4658 (Eteplirsen)
Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
Other Name: EXONDYS 51
- Percent of dystrophin positive fibers [ Time Frame: Baseline to Week 20 ]The primary biological efficacy endpoint will be the change from baseline at Week 20 in the percent of dystrophin positive fibers (type = anti-dystrophin antibody MANDYS106) in muscle biopsy tissue as measured by immunohistochemistry (IHC).
- 6 Minute Walk Test (6MWT) [ Time Frame: Baseline to Week 212 ]The primary functional efficacy endpoint will be the change from baseline to Week 212 on the 6 Minute Walk Test (6MWT).
- Muscle Biopsy Tests [ Time Frame: Baseline to Week 20, Week 140 (optional) ]
- Dystrophin intensity per fiber in muscle biopsy tissue as determined by IHC
- CD3, CD4, and CD8 lymphocyte count in muscle biopsy tissue
- Total dystrophin protein in muscle biopsy tissue as determined by Western blot analysis
- Exon skipping in muscle biopsy tissue as assessed by reverse transcriptase polymerase chain reaction (RT PCR).
- Timed 4 Step Test results [ Time Frame: Baseline to Week 212 ]
- North Star Ambulatory Assessment (NSAA) results [ Time Frame: Baseline to Week 212 ]
- Maximum voluntary isometric contraction test (MVICT) results [ Time Frame: Baseline to Week 212 ]
- 9 Hole Peg Test results [ Time Frame: Baseline to Week 212 ]
- Pediatric Quality of Life Inventory (PedsQL) results, including the neuromuscular module (NMM) [ Time Frame: Baseline to Week 212 ]
- Pulmonary function test results [ Time Frame: Baseline to Week 212 ]including forced vital capacity (FVC), percent predicted FVC, forced expiratory volume in 1 second (FEV1), FEV1%, FEV1/FVC ratio, maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01540409
|United States, California|
|Miller Children's Hospital|
|Long Beach, California, United States, 90806|
|United States, Florida|
|University of Florida Clinical Research Center|
|Gainesville, Florida, United States, 32610|
|United States, Illinois|
|Rush University Medical Center|
|Chicago, Illinois, United States, 60612|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Missouri|
|Washington University Medical School|
|St. Louis, Missouri, United States, 63110|
|United States, New York|
|Summerwood Pediatrics/Infusacare Medical Services|
|Liverpool, New York, United States, 13088|
|United States, North Carolina|
|Levine Children's Hospital|
|Charlotte, North Carolina, United States, 28203|
|United States, Ohio|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|United States, Pennsylvania|
|Children's Hospital of Pittsburgh of UPMC|
|Pittsburgh, Pennsylvania, United States, 15224|
|United States, Virginia|
|Children's Specialty Group, Pediatric Neurology|
|Norfolk, Virginia, United States, 23510|
|United States, Wisconsin|
|Osceola Medical Center|
|Osceola, Wisconsin, United States, 54020|
|Principal Investigator:||Jerry R Mendell, MD||Nationwide Children's Hospital|